Type 2 Diabetes Mellitus
Conditions
Interventions
Telmisartan (20-80 mg/day, 12 months)
Sponsors
Kagawa University, Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Diabetes mellitus - FBS >= 126 mg/dL - 75g OGTT (2 hours) >= 200 mg/dL - PPG >= 200 mg/dL 2) Patients who have not been treated with an anti-hypertensive drug within 4 weeks
Exclusion criteria
Exclusion criteria: 1) Type 1 diabetes mellitus 2) Pregnancy 3) Severe renal disease (CCr<30 mL/min, sCr >= 2.0 mg/dL) 4) Severe hepatic disease (GOT >= 150 IU or GPT >= 150 IU) 5) Endocrine disease 6) Patients with malignant tumor 7) Patients inadequate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) AGT (urine and serum): 0, 6 and 12 months 2) Albumin (urine): 0, 6 and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) BP: 0, 2, 4, 6, 8, 10 and 12 months 2) BW, BMI, waist circumference:0, 6 and 12 months 3) FBS, insulin, HbA1c: 0, 6 and 12 months 4) PRA, Aldosterone: 0 and 12 months 5) T-chol, LDL-chol, HDL-chol, TG: 0 and 12 months 6) Cr, BUN, UA: 0, 6 and 12 months 7) Cardiovascular events: 0-12 months 8) Insulin sensitivity: 0, 6 and 12 months 9) hsCRP: 0, 6 and 12 months | — |
Countries
Japan
Contacts
Public ContactHirofumi Hitomi
Kagawa University, Faculty of Medicine Department of Pharmacology
Outcome results
None listed